Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Compliance 360° Part 2: Getting The Most Out Of Inspection Close-Out Meetings

Executive Summary

This is Compliance 360°, a podcast series from Medtech Insight on US FDA compliance and enforcement issues. In this second installment, former FDA investigations branch director Ricki Chase explains steps your firm should take to make sure inspection close-out meetings are fruitful for everyone involved.

Ricki Chase recognizes that US FDA inspection close-out meetings can be tense and fraught with chilly moments.

“The close-out is rarely viewed as a joyous event where you shake hands [with FDA investigators] and go back about your normal business,” Chase says in the second installment of Compliance 360°, a podcast series from Medtech Insight on US FDA compliance and enforcement issues.

Rather, “the close-out meeting is an opportunity to gain an understanding of the investigator's observations. This is a time where spoken word is often more valuable than the written one. It gives insight into the investigator's level of concern, which translates into the tone and presentation of the official Establishment Inspection Report.”

In the podcast, Chase – a former FDA investigations branch director – explains steps your firm should take to make sure inspection close-out meetings are fruitful for everyone involved.

“If you are one of the fortunate ones who do not receive an FDA-483 [inspection form], keep listening – there's still value in the close-out,” she implores. “And if you're less fortunate and receive a 483, keep listening – there's value in the close-out.”

Chase is compliance practice director for Lachman Consultant Services, a firm she joined in June 2016 after spending 16 years at FDA, where she was also an investigator, medical device specialist and supervisory investigator.

Listen to the podcast via the player below:

 

Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

MT104425

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel